UmaNarayanasamiMD

Oncology • Concord, MA

Dana-Farber Cancer Institute at St. Elizabeth's Medical Center

Join to view full profile

Dr. Narayanasami is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Narayanasami's full profile

Already have an account?

Office
MGH Cancer Center
131 ORNAC, JCB 200
Concord, MA 01742
Phone+1 978-287-3436

Fax+1 978-287-3642
Is this information wrong?

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
Tufts Medical CenterResidency, Internal Medicine, 1997 - 1998
Brown UniversityResidency, Internal Medicine, 1995 - 1997
Madras Medical CollegeClass of 1993

Certifications & Licensure

MA State Medical License 2001 - 2025
RI State Medical License 1996 - 1997
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 3
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2010 Feb 01
Terminated
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

21 citations
Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset.
V. Sasisekharan, Niharika Pentakota, Akila Jayaraman, Kannan Tharakaraman, Gerald N. Wogan, Uma Narayanasami> ;Proceedings of the National Academy of Sciences of the United States of America. 2021 Feb 2
1 citations
Rare Pedal Manifestation of Diffuse Multiple Myeloma Lesions
Benjamin M. Saviet, John T. Marcoux, Uma Narayanasami> ;The Journal of Foot and Ankle Surgery. 2017 Mar 1
2 citations
Recovery of kidney function following delayed use of theralite™ dialyzer in a patient with myeloma cast nephropathy
Khagendra Dahal, Shani Shastri, Uma Narayanasami, Vanesa Bijol, Karen Rider, James A. Strom, Bertrand L. Jaber> ;Clinical Nephrology. 2013 Apr 1
503 citations
Roles of heparan-sulphate glycosaminoglycans in cancer
Ram Sasisekharan, Zachary Shriver, Ganesh Venkataraman, Uma Narayanasami> ;Nature Reviews. Cancer. 2002 Jul 1
121 citations
Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation
Uma Narayanasami, Rajani Kanteti, Julie Morelli, Alanna Klekar, Asma Al-Olama, Claire Keating, Colleen O'Connor, Eugene M. Berkman, John K. Erban, Kellie Sprague, Kenn...> ;Blood. 2001 Oct 1
Join now to see all

Press Mentions

Concord Resident Seeks Typical Life After Breast Cancer DiagnosisOctober 10th, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Dana-Farber Cancer InstituteBoston, Massachusetts
St. Elizabeth's Medical CenterBrighton, Massachusetts
Massachusetts General HospitalBoston, Massachusetts
Emerson HospitalConcord, Massachusetts
Beth Israel Deaconess Hospital-NeedhamNeedham, Massachusetts